Autolus Therapeutics plc
AUTL- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001730463
In the last 90 days, Autolus Therapeutics plc insiders filed 0 open-market purchases and 1 sale; 83 institutions reported holding it in 13F filings for Q2 2026, worth $212.0M in total; no superinvestor holds it.
Key figures
- Market capADS ratio not in SEC data
- –
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $15.7K in total
- 1
- 13F holdersQ2 2026, −1 vs. previous quarter
- 83
- 13F valueReported value at the end of Q2 2026
- $212.0M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $75.4M
- +644.9% year over year
- Net income, FY2025
- -$287.5M
- No comparable prior period
- Free cash flow, FY2025
- -$302.6M
- No comparable prior period
- Revenue, Q3 FY2026
- $41.2M
- +94.6% year over year
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 8.63M
- Shares sold short
- Change
- −436.8K
- −4.8% vs. previous
- Days to cover
- 4.73
- At average daily volume
Superinvestors holding AUTL, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AUTL at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Autolus Therapeutics plc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 3, 2026 (view filing)4:36 PM ET | Sep 2 | 1 day | Piccina CintiaU.S. CCO & Country Gen Manager | SSaleAmerican Depositary Shares | −6.71K | $2.34 | −$15.7K | −33.6%13.3K after |
Top 10 13F holders, Q2 2026
See all 83 holdersThe largest institutional positions in Autolus Therapeutics plc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Mak Capital One LLC | 33,621,487 | $53.8M | 7.54% | 00.0% | Unchanged |
| Blackstone Group Inc. | 20,485,611 | $32.8M | 0.09% | 00.0% | Unchanged |
| Syncona Portfolio Ltd | 16,640,720 | $26.6M | 100.00% | 00.0% | Unchanged |
| Armistice Capital, LLC | 15,000,000 | $24.0M | 0.66% | −800,000−5.1% | Reduced |
| Polygon Management Ltd. | 9,500,000 | $15.2M | 2.47% | 00.0% | Unchanged |
| Schroder Investment Management Group | 7,833,282 | $12.9M | 0.01% | −1,656,063−17.5% | Reduced |
| Frazier Life Sciences Management, L.P. | 4,447,910 | $7.12M | 0.15% | 00.0% | Unchanged |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 3,361,156 | $5.38M | 0.01% | 00.0% | Unchanged |
| Laurion Capital Management LP | 3,316,626 | $5.31M | 0.38% | 00.0% | Unchanged |
| Renaissance Technologies LLC | 1,984,700 | $3.18M | 0.00% | −314,799−13.7% | Reduced |
Holders of 5% or more of AUTL
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Autolus Therapeutics plc.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| MAK Capital Fund LP | 13G/A | 12.60%33.6M shares | +1.30 ppfrom 11.30% | Jun 25, 20254 filings | May 15, 2026 | SEC |
| Syncona Portfolio Ltd | 13G/A | 10.80%28.8M shares | – | Feb 12, 20216 filings | May 7, 2025 | SEC |
| Blackstone Group Inc. | 13D/A | 7.60%20.5M shares | – | Nov 16, 20214 filings | Nov 10, 2026 | SEC |
| Armistice Capital, LLC | 13G/A | 5.64%15.0M shares | −0.30 ppfrom 5.94% | Feb 14, 20236 filings | Aug 14, 2026 | SEC |
| PPF Group a.s. | 13D/A | 5.60%14.8M shares | – | Oct 25, 20242 filings | Aug 28, 2026 | SEC |